Lakefront Biotherapeutics (GLPGF) Non-cash Items (2016 - 2017)
Lakefront Biotherapeutics' (GLPGF) quarterly Non-cash Items came in at -$18.4 million in Q2 2017, down 425.67% year-over-year from $5.6 million in Q2 2016, and down 132.37% quarter-over-quarter from -$7.9 million in Q1 2017.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Non-cash Items (2016 - 2017) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Non-cash Items for 2 consecutive years, with -$18.4 million the latest figure, recorded in Q2 2017.
- On a quarterly basis, Non-cash Items fell 425.67% year-over-year to -$18.4 million in Q2 2017; TTM through Jun 2017 was -$46.5 million, a N/A change from a year earlier, with the FY2016 full-year figure at $5.7 million, up 106.34% from the prior year.
- Non-cash Items was -$18.4 million for Q2 2017 at Lakefront Biotherapeutics, down from -$7.9 million in the prior quarter.
- Over five years, Non-cash Items peaked at -$3.5 million in Q2 2016 and troughed at -$18.4 million in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | -18.36 Mn |
| Mar 31, 2017 | -7.90 Mn |
| Jun 30, 2016 | -3.49 Mn |
| Mar 31, 2016 | -16.77 Mn |